BIVI Overview

Delcath Systems' Buyback Announcement: Delcath Systems saw a 4.02% increase in after-hours trading to $8.52 following the announcement of a $25 million share repurchase program, indicating confidence in its long-term outlook.

BioVie Inc. Gains Despite No News: BioVie Inc. rose 13.39% to $1.44 in extended trading, rebounding from a decline during the regular session, with the increase attributed to speculative trading rather than new company-specific news.

Cassava Sciences' After-Hours Rally: Cassava Sciences advanced 9.17% to $2.87 after hours, recovering from a regular session drop, as investors reacted to its recent Q3 results showing a reduced net loss and significant cash reserves.

Enlivex Therapeutics' Modest Increase: Enlivex Therapeutics experienced a 4.24% rise to $0.95 in after-hours trading, despite no new developments reported on Thursday.

Webinar Announcement: BioVie Inc. is hosting a webinar on December 9, 2025, featuring CEO Cuong Do, who will discuss the company's drug candidate bezisterim and its potential in treating neurological diseases and liver complications.

Drug Development Focus: Bezisterim targets inflammation and insulin resistance linked to Alzheimer's, Parkinson's, and Long COVID, while BIV201 is an orphan drug candidate for refractory ascites, currently in late-stage clinical development.

Market Potential: BioVie is advancing multiple late-stage clinical programs with promising safety data and significant market opportunities, positioning the company for potential value creation through upcoming milestones and partnerships.

Forward-Looking Statements: The press release includes forward-looking statements regarding the company's expectations and potential risks, emphasizing that actual results may differ from projections due to various factors.

Investor Alert: Bragar Eagel & Squire, P.C. is investigating potential claims against BioVie Inc. (BIVI) for long-term stockholders who may have suffered losses between August 5, 2021, and November 29, 2023, following a class action complaint regarding breaches of fiduciary duties by the company's board.

Clinical Trial Issues: BioVie disclosed significant protocol deviations and Good Clinical Practice violations in its Phase 3 clinical trial for NE3107, leading to a 60% drop in share price after the trial failed to achieve statistical significance due to the exclusion of patients from the trial.

Investor Webinar Announcement: BioVie Inc. will host an investor webinar on October 8, 2025, featuring CEO Cuong Do discussing their drug candidate bezisterim, which targets inflammation and insulin resistance related to Alzheimer's, Parkinson's, and long COVID.

Clinical Progress and Drug Development: The company is advancing its late-stage orphan drug candidate BIV201 for liver cirrhosis and has several clinical programs underway, with encouraging safety data and potential partnerships being evaluated.